Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M16.8Revenue (TTM) $M0.0Net Margin (%)-54,190.0Altman Z-Score-84.7
Enterprise Value $M13.2EPS (TTM) $-0.6Operating Margin %-54,190.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-54,190.0Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-18.8Quick Ratio1.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-5.6Current Ratio1.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-187.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-309.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M37.6ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

RPRX is held by these investors:



RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-12-09Buy20,000$1.6-71.88view
Masterson Nola EDirector 2016-11-21Sell3,305$1.95-76.92view
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.93-51.61view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.18-61.86view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-95.22view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-95.22view
Masterson Nola EDirector 2014-09-15Buy200$14.34-96.86view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-96.76view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-96.75view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-96.99view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Repros Therapeutics Inc.® Reports Second Quarter 2017 Financial Results Aug 14 2017 
Lifshitz & Miller LLP Announces Investigation of Acacia Communications, Inc., AngioDynamics, Inc., Jul 24 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Repros Therapeutics Jul 17 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repros Therapeut Jul 17 2017 
Repros Announces Proellex® Development Program Will Remain on Partial Clinical Hold by the FDA Jul 17 2017 
Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results May 09 2017 
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Apr 17 2017 
Repros Names Larry Dillaha, M.D., its Permanent President and CEO Apr 10 2017 
Company Holds Meeting with FDA to Discuss Oral Proellex® in the Treatment of Uterine Fibroids Apr 10 2017 
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2016 Financial Results Mar 31 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK